https://medicine.ouhsc.edu/academic-departments Parent Page: Academic Departments id: 21856 Active Page: Clinical Researchid:21962

Clinical Research

The character of the Department of Obstetrics & Gynecology’s research staff is evidenced by the continuing success of this core mission. The research office is committed to supporting faculty, residents, and medical students in all of their clinical trial and research endeavors.  The departmentally based research staff currently consists of four section-dedicated research nurses, one data manager and regulatory specialist, one lab assistant/ data manager, and a research manager. In addition, the department’s Gynecology Oncology section collaborates with the Peggy and Charles Stephenson Oklahoma Cancer Center’s Clinical Trials Office and their resource of over 50 qualified research staff.      

The staff provides a number of valuable research-related services for the Department of OB/GYN.  In addition to the patient-related tasks carried out by the nursing staff, (patient recruitment, documenting, and reporting), research personnel also assist our investigators in the creation and design of protocols and consent forms, tracking and reporting databases and data entry.  The staff is also responsible for assisting investigators in every aspect of their industry-sponsored trials including all of the data submission and correction, Institutional Review Board submissions and the facilitation of contract negotiations.  

The Department of OB/GYN has secured and identified multiple federal, industry, foundation, state, and local opportunities for research funding. Specifically, the department’s research ventures concentrate on the following areas of focus: unexplained infertility; PCOS; lifestyle factors and ovarian reserve; gastroschisis; PPROM; thrombophillia in pregnancy; diagnostic tests for high risk pregnancies; 3D ultrasound and pelvic floor muscles; stress urinary incontinence; overactive bladder; fecal incontinence; prolapse; ovarian, cervical and endometrial cancers; phase I and early drug development for targeted therapies, QOL and supportive care.

While carrying out the above mission, our investigators and research staff remain committed to the protection and safety of all human participants, as well as the application of all federal regulations and ethical principles with respect to research and clinical trials.